The backers were not disclosed.
The company intends to use the funds to further develop the device prototype for clinical use, and to begin a lung transplant trial at the University of Alberta.
Led by Kevin Ens, CEO, Tevosol has designed a medical device that keeps critical organs such as hearts and lungs viable for transplant longer.
The company’s product keeps the organ warm and supplied with oxygen, and extends its out of body life. The system consists of a common hardware platform with organ-specific single-use disposable cassettes for lungs, hearts, livers and kidneys.
Tevosol is a University of Alberta spinoff company.